| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10910921 | Lung Cancer | 2014 | 6 Pages |
Abstract
Selected patients with IIIA NSCLC treated with TT had favorable long-term survival with acceptable short-term mortality. These outcomes support the decision-making and function of our MTB/treatment team. The role of TT in cN2 disease and large tumors merits further evaluation.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
C. Dickhoff, K.J. Hartemink, P.M. van de Ven, E.J.F. van Reij, S. Senan, M.A. Paul, E.F. Smit, M. Dahele,